Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, this new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood.

Liquid biopsy firm SeekIn said Monday that it has received a CE mark for its cancer recurrence monitoring test, SeekInCure, and is preparing to launch assay kits in the European Union and other countries that recognize the designation.

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Biodesix said Monday that it has been awarded a US Federal Supply Schedule contract for cancer testing of covered patients served by the Veterans Health Administration and Military Health System.

Illumina said on Tuesday that it has entered into a strategic research collaboration with AstraZeneca on drug target discovery.

Thermo Fisher Scientific said on Tuesday that its next-generation sequencing-based Oncomine Dx Target Test has been approved by the US FDA as a companion diagnostic (CDx) to identify patients with advanced RET-driven lung and thyroid cancers who may be eligible for Lilly’s Retevmo (selpercatinib).

German firm Oncgnostics said on Thursday that China's National Medical Products Administration approved its DNA methylation-based cervical cancer GynTect assay.

Pillar Biosciences said Monday that China's National Medical Products Administration has granted commercial approval for its OncoReveal Dx Colon Cancer Assay.

Guardant Health and Thermo Fisher Scientific said on Friday that the US Food and Drug Administration has granted premarket approvals for their respective next-generation sequencing assays as companion diagnostics to Enhertu (trastuzumab deruxtecan)

MDxHealth said on Tuesday that it has acquired the Oncotype DX GPS prostate cancer testing business from Exact Sciences subsidiary Genomic Health in a deal worth up to $100 million.